Skip to contents

Note that objects should not be created by users, therefore no initialization function is provided for this class.

Slots

targetEndOfTrial

the target probability of DLE wanted at the end of a trial

targetDoseEndOfTrial

the dose level corresponds to the target probability of DLE wanted at the end of a trial, TDEOT

targetDoseEndOfTrialAtDoseGrid

the dose level at dose grid corresponds to the target probability of DLE wanted at the end of a trial

targetDuringTrial

the target probability of DLE wanted during a trial

targetDoseDuringTrial

the dose level corresponds to the target probability of DLE wanted during the trial. TDDT

targetDoseDuringTrialAtDoseGrid

the dose level at dose grid corresponds to the target probability of DLE wanted during a trial

TDEOTSummary

the six-number table summary, include the lowest, the 25th precentile (lower quartile), the 50th percentile (median), the mean, the 27th percentile and the highest values of the final dose levels obtained corresponds to the target probability of DLE want at the end of a trial across all simulations

TDDTSummary

the six-number table summary, include the lowest, the 25th precentile (lower quartile), the 50th percentile (median), the mean, the 27th percentile and the highest values of the final dose levels obtained corresponds to the target probability of DLE want during a trial across all simulations

FinalDoseRecSummary

the six-number table summary, include the lowest, the 25th precentile (lower quartile), the 50th percentile (median), the mean, the 27th percentile and the highest values of the final optimal doses, which is either the TDEOT when only DLE response are incorporated into the escalation procedure or the minimum of the TDEOT and Gstar when DLE and efficacy responses are incorporated, across all simulations

ratioTDEOTSummary

the six-number summary table of the final ratios of the upper to the lower 95% credibility intervals of the final TDEOTs across all simulations

FinalRatioSummary

the six-number summary table of the final ratios of the upper to the lower 95% credibility intervals of the final optimal doses across all simulations #@slot doseRec the dose level that will be recommend for subsequent study

nsim

number of simulations

propDLE

proportions of DLE in the trials

meanToxRisk

mean toxicity risks for the patients

doseSelected

doses selected as MTD (targetDoseEndOfTrial)

toxAtDosesSelected

true toxicity at doses selected

propAtTargetEndOfTrial

Proportion of trials selecting at the doseGrid closest below the MTD, the targetDoseEndOfTrial

propAtTargetDuringTrial

Proportion of trials selecting at the doseGrid closest below the targetDoseDuringTrial

doseMostSelected

dose most often selected as MTD

obsToxRateAtDoseMostSelected

observed toxicity rate at dose most often selected

nObs

number of patients overall

nAboveTargetEndOfTrial

number of patients treated above targetDoseEndOfTrial

nAboveTargetDuringTrial

number of patients treated above targetDoseDuringTrial

doseGrid

the dose grid that has been used

fitAtDoseMostSelected

fitted toxicity rate at dose most often selected

meanFit

list with the average, lower (2.5%) and upper (97.5%) quantiles of the mean fitted toxicity at each dose level

stop_report

matrix of stopping rule outcomes